Lilly’s Amyvid receives European approval
European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.
Pharmaceutical
Articles
Lilly competitor gets backing on diabetes drug
Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.
Lilly settles with four sisters in DES cancer case
Four sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.
Drug sold by Lilly caused cancer, women claim at Boston trial
In opening statements Tuesday, a lawyer for Indianapolis-based Lilly told the jury there is no evidence the synthetic estrogen known as DES causes breast cancer in the daughters of women who took it.
Indiana to receive nearly $793K in Amgen settlement
Amgen Inc. has agreed to pay Indiana nearly $793,000 as part of a larger settlement to resolve allegations it paid kickbacks to physicians who prescribed some of its drugs for unapproved uses.
Lilly OKs $1.5B share buyback, first quarter dividend
Indianapolis-based drugmaker Eli Lilly and Co. said Monday that its board authorized a $1.5 billion share-repurchase program, which the company expects to complete next year.
Lilly finds solace in new Alzheimer’s study
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
Lilly discontinues late-stage trial in rheumatoid arthritis
Eli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
Lilly plans another study for Alzheimer’s drug
Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.
Lilly chief says China too slow in approving new drugs
China takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
EU reviews cancer drug from Endocyte, Merck
Merck & Co. and Endocyte Inc. said Tuesday that European Union regulators will review their drug vintafolide as a treatment for ovarian cancer.
Drugmakers collaborate to facilitate drug tests
Eli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests of experimental drugs up and running more quickly and efficiently.
Indy loses promising health startup
LabDoor, which soon will launch an iPhone app that assigns A-F grades to over-the-counter vitamins and medicines, moved last month from Indianapolis to San Francisco, where it received $100,000 in startup financing.
Lilly to spend $140M on new insulin cartridge plant
About 100 workers will staff the new plant, which will be constructed by spring 2014 and ready for operations in 2015. But only “some” of that number will be new hires.
Lilly’s Cialis receives European approval for new use
The European Union has approved Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
Lilly’s insulin dip concerns analysts
Eli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter earnings report: Lilly’s insulin sales are down.
Lilly continues string of positive trials
Eli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
Lilly says experimental diabetes drug outperformed rivals
Eli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
Alzheimer’s prevention seen promising as drug cures fail
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
Lilly stomach-cancer drug helps survival, study finds
Eli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer drug helped patients with advanced disease live longer.